

李朋梅 药剂学硕士，副主任药师，北京大学药学院临床药学专硕硕士生导师

联系方式：（010）84205370；13466320146

lipengmei@yeah.net

中日友好医院

药学部 副主任，党支部书记

中国药学会医院药学专业委员会委员

中国药学会医药信息专业委员会委员

中国药理学会治疗药物监测研究专业委员会委

中华中医药学会中药毒理与安全性研究分会委员

**研究方向：**

药代动力学研究、治疗药物监测及个体化用药

**主要工作：**全面负责完成了免疫抑制剂霉酚酸、抗感染药物美罗培南、亚胺培南、多粘菌素、头孢他啶、伏立康唑、氟康唑、泊沙康唑、替考拉宁等10余项治疗药物监测药物的方法建立和临床应用，开展了相关的群体药代动力学研究，为特殊人群用药的安全有效提供有力技术支撑。专业业特长：(1)呼吸系统疾病的药物治疗管理，如慢性阻塞性肺部疾病、哮喘、慢性支气管炎等疾病的药物治疗管理、吸入装置的用药教育、依从性的评估等。(2)器官移植患者免疫抑制剂的药物治疗管理，如肾移植术后、肺移植术后多种药物合并使用的治疗方案重整，患者健康教育等。(3)擅长基于治疗药物监测结果进行个体化给药方案设计。

**研究成果：**承担国家重点研发计划子课题1项 ,留学归国人员科技活动计划启动项目1项，北京市科委合作课题1项，中日医院院级课题1项，参与国家自然科学基金青年项目、北京市自然科学基金项目9项。发表论文情况：在Transpl Int.， Behav Pharmacol.，Antimicrob Agents Chemother.，中国药房、中国药学杂志、中国新药杂志等药学期刊发表论著30余篇。

**代表性成果：**

1Wang Xiaoxue,Qin Wei,Chen Wenqian,Liu Huifang**,Li Pengmei\*.**Validation of a novel UPLC-HRMS method for human whole-blood cyclosporine and comparison with a CMIA immunoassay .EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21(3):191.

2 Du Wen-Wen,Wang Xiao-Xing,Zhang Dan,Chen Wen-Qian**,Li Peng-Mei\*.** Retrospective analysis on incidence and risk factors of early onset acute kidney injury after lung transplantation and its association with mortality .RENAL FAILURE,2021,43(1):535-542..

3 Chen Wenqian,Liu Huifang,Wang Qianlin,Wang Xiaoxing, **Li Pengmei\***.Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia .EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77(1):95-105..

4 Qin Wei,Wang Xiaoxue,Chen Wenqian,Du Wenwen, **Li Pengmei\*.** An in vitro approach to simulate the process of 5-fluorouracil degradation with dihydropyrimidine dehydrogenase: the process in accordance to the first-order kinetic reaction .XENOBIOTICA, 2021, 51(1):24-30.

5 Zhang Dan,Hu Min,Xu Chengbo,Chen Chengjuan, **Li Pengmei\***.Pharmacokinetic Characterization of ZT55, A Novel Indole Derivative Isolated from Radix Isatidis, using Liquid Chromatography/Tandem Mass and Q-TOF/Tandem Mass Spectrometry .CURRENT PHARMACEUTICAL ANALYSIS, 2021,17(2):210-221.

6 Qin W, Zhang L, Xu L, Zhao L, Yang Q, **Li P\*,** Fan B\*. Effect of Continuing Nursing Education on the Quality of Nursing Management of Cancer Pain in China. J Contin Educ Nurs. 2021 Nov;52(11):535-540.

7 Wang Xiaoxing,Du Wenwen,Zhang Xianglin\*,**Li Pengmei\***. T.he Influence of Different Disease States on Rituximab Pharmacokinetics .CURRENT DRUG METABOLISM, 2020,21(12):938-946.

8 Zhang Dan,Ding Yangming,Wang Xiaoxue,Xin Wenyu, **Li Pengmei\*.** Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin .EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020,76(7):939-946..

9 Chen Wenqian,Zhang Dan,Lian Wenwen,Wang Xiaoxue, **Li Pengmei\*.**Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64(6).

10Qin Wangjun,Zhang Lei,Tang Kun,Zhao Li, **Li Pengmei\*.**Effect of heat shock protein 70 modulators on the development of morphine analgesic tolerance in rats .BEHAVIOURAL PHARMACOLOGY, 2020,31(2-3):179-185.

11张丹,陈文倩,秦伟,杜雯雯,**李朋梅**\*.利伐沙班导致出血事件的群体药动学模型建立及影响因素分析 .中国医院药学杂志, 2021，41 (14):1446-1449.

12杜雯雯,王晓星,张丹,**李朋梅\*.**肺移植患者术后使用他克莫司1年CYP3A5、CYP3A4、ABCB1、POR~\*28基因多态性与他克莫司个体化用药的关系研究 .中国药房, 2020, 31(1):80-85.

13张丹,辛文妤,杜雯雯,陈文倩, **李朋梅\*.**SLCO1B1和APOE基因多态性对瑞舒伐他汀调脂疗效及不良反应的影响 .中国新药与临床杂志, 2020,39(1):31-36.

14陈文倩,刘慧芳,王芊霖,王晓星, **李朋梅\*.**基于治疗药物监测的多粘菌素B用药方案优化 .中国新药杂志, 2020, 29(7):836-840.

15陈文倩,王晓雪,刘慧芳,杜雯雯, **李朋梅\***.有限采样法估算重症感染患者卡泊芬净的药-时曲线下面积 .中国药业, 2020, 29(13):9-13.

16王晓雪,刘慧芳,秦伟,张丹, **李朋梅\***.不同品牌蛋白沉淀板对人血浆中霉酚酸含量测定结果比较. 中国医院药学杂志:2021,1-6.

17陈文倩,王晓雪,刘慧芳,杜雯雯, **李朋梅\*.**2型糖尿病肾病及非肾病患者同型半胱氨酸及叶酸等9种维生素水平分析 .中国药学杂志, 2020,55(14):1154-1157.

18.Zhang Dan,Chen Wenqian,Qin Wei,Du Wenwen,&**Li Pengmei.(2023)**.Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation .JOURNAL OF CLINICAL PHARMACOLOGY,63(1):66-76.